Alzheimers Disease and Related Disorders Association Inc

Research - see schedule o for detailsresearchthe alzheimer's association is at the forefront of the alzheimer's scientific field, globally connecting researchers in the quest to find methods of diagnosis, treatment, prevention and ultimately cures for all the diseases that cause cognitive impairment and dementia. the alzheimer's association implements an aggressive global research and science program strategically designed to accelerate progress by fostering innovation, identifying and closing critical knowledge gaps, developing and disseminating tools, and nurturing scientific talent.as the largest nonprofit funder of alzheimer's and dementia research, the alzheimer's association is committed to accelerating the global progress of new treatments, preventions and, ultimately, a cure. with over 20 funding programs offered across the entire spectrum of science to investigators at all career-levels, the alzheimer's association is currently committed to over $450 million to over 1,200 projects in 56 countries. in addition, the alzheimer's association's part the cloud funding program is designed to accelerate the transition of potential therapies from laboratory testing to clinical trials. since 2012, the part the cloud initiative has raised nearly $90 million to accelerate scientific progress in funding the most promising early phase clinical studies.the alzheimer's association seeks to fund and advance best-in-class research and works with collaborators around the globe from all sectors to hasten this progress. an example of the high risk, high reward funding, the alzheimer's association funded the development pittsburgh compound b (pib), the first radiotracer capable of showing beta-amyloid in the living brain during a positron emission tomography (pet) scan. this sppurred significant investment in this area of research, leading to three now fda-approved tracers for amyloid pet. identifying beta-amyloid in the living brain can be used to support the diagnosis of alzheimer's and also lets researchers determine if an experimental drug successfully decreases this hallmark alzheimer's protein providing invaluable information about disease progression. another example, the alzheimer's association u.s. study to protect brain health through lifestyle intervention to reduce risk (u.s. pointer) is a two-year clinical trial to evaluate whether lifestyle interventions that simultaneously target many risk factors protect cognitive function in older adults who are at increased risk for cognitive decline. u.s. pointer is the first study of its kind to be conducted in a large diverse and representative group of americans across the country. this landmark study reported out the topline results in july 2025, demonstrating that two lifestyle interventions targeting a combination of physical activity, improving nutrition, cognitive and social challenge and health monitoring improved cognition in older adults at risk of cognitive decline. further, while both interventions improved cognition, the cognitive benefits were even greater for the partiicpants in the more structured intervention group, helping to protect thinking and memory from the normal decline that often comes with aging over the two-year period of the study. the alzheimer's association has also launched the nation's first alzheimer's network for treatment and diagnostics (alz-net) which is a voluntary health care provider-enrolled patient network that collects clinical and safety data for patients treated with new fda-approved alzheimer's disease therapies and tracks the long-term health outcomes associated with their use in real-world settings.alz-net is a resource for evidence gathering, information sharing and education across the clinical and research communities to help improve brain health outcomes for patients.the alzheimer's association has been a catalyst and convener for more than 40 years. the alzheimer's association offers year-round opportunities for the scientific commun